CIRM provides funding across five key areas: Infrastructure, Education, Discovery Research, Translational Research, and Clinical Research. By supporting projects at every stage of development, from initial discovery to clinical trials, CIRM drives progress in regenerative medicine and accelerates innovative therapies to patients.
Check out our portfolio of awards below. Click here to see a list of People We’ve Funded. Click here to see a list of our Funded Institutions.
All CIRM Grants
Search Filters »
| Institution |
Researcher name |
Grant Type |
Grant Title |
Award Value |
| Stanford University |
Dr. Howard Y. Chang |
New Faculty I |
Noncoding RNAs in Cell Fate Determination |
$2,985,894 |
| BioTime, Inc. |
Dr. Michael D West Ph.D. |
Early Translational I |
Addressing the Cell Purity and Identity Bottleneck Through Generation and Expansion of Clonal Human Embryonic Progenitor Cell Lines |
$4,721,706 |
| University of California, Davis |
Dr. Alice F Tarantal |
Early Translational I |
In Utero Model to Assess the Fate of Transplanted Human Cells for Translational Research and Pediatric Therapies |
$3,143,392 |
| Salk Institute for Biological Studies |
Dr. Inder M. Verma |
Early Translational I |
Curing Hematological Diseases |
$5,979,252 |
| Sanford Burnham Prebys Medical Discovery Institute |
Dr. Evan Y. Snyder |
Early Translational I |
Developmental Candidates for Cell-Based Therapies for Parkinson’s Disease (PD) |
$5,190,752 |
| Stanford University |
Dr. Jill Helms |
Early Translational I |
Enhancing healing via Wnt-protein mediated activation of endogenous stem cells |
$6,464,126 |
| Jackson Labs |
Pali G. Kaur |
Early Translational I |
Mouse Models for Stem Cell Therapeutic Development |
$3,759,134 |
| Gladstone Institutes, J. David |
Dr. Warner C Greene |
Early Translational I |
Maximizing the Safety of Induced Pluripotent Stem Cells as an Infusion Therapy: Limiting the Mutagenic Threat of Retroelement Retrotransposition during iPSC Generation, Expansion and Differentiation |
$1,280,001 |
| Scripps Research Institute |
Dr. Martin Friedlander |
Early Translational I |
Autologous Retinal Pigmented Epithelial Cells Derived from Induced Pluripotent Stem Cells for the Treatment of Atrophic Age Related Macular Degeneration |
$5,806,321 |
| University of California, Los Angeles |
Dr. Gabriel H. Travis |
Early Translational I |
Development of a Stem Cell-based Transplantation Strategy for Treating Age-related Macular Degeneration |
$5,487,136 |
| Scripps Research Institute |
Dr. Jeanne F Loring |
Early Translational I |
Ensuring the safety of cell therapy: a quality control pipeline for cell purification and validation |
$5,830,771 |
| ViaCyte, Inc. |
Dr. Olivia G. Kelly |
Early Translational I |
Methods for detection and elimination of residual human embryonic stem cells in a differentiated cell product |
$5,405,397 |
| Scripps Health |
Dr. Darryl D. D’Lima |
Early Translational I |
Stem Cell-Based Therapy for Cartilage Regeneration and Osteoarthritis |
$3,118,431 |
| University of California, Irvine |
Dr. Frank LaFerla |
Early Translational I |
Neural Stem Cells as a Developmental Candidate to Treat Alzheimer Disease |
$3,599,997 |
| University of California, Davis |
Dr Jan A Nolta |
Early Translational I |
Sustained siRNA production from human MSC to treat Huntingtons Disease and other neurodegenerative disorders |
$2,615,674 |
| University of California, San Diego |
Dr. Yang Xu |
Early Translational I |
Developing induced pluripotent stem cells into human therapeutics and disease models |
$5,165,028 |
| Parkinson’s Institute |
Mr. James “Bill” William Langston Mr. |
Early Translational I |
Using patient-specific iPSC derived dopaminergic neurons to overcome a major bottleneck in Parkinson’s disease research and drug discovery |
$3,698,646 |
| University of California, Berkeley |
Dr. Ellen A. Robey |
Transplantation Immunology |
Human Immune System Mouse models as preclinical platforms for stem cell derived grafts |
$1,005,605 |
| Scripps Research Institute |
Dr. Nicholas R.J. Gascoigne |
Transplantation Immunology |
Role of Innate Immunity in hematopoeitic stem cell-mediated allograft tolerance |
$1,705,554 |
| Stanford University |
Dr. Kenneth Weinberg |
Transplantation Immunology |
Engineered immune tolerance by Stem Cell-derived thymic regeneration |
$1,271,729 |
| University of California, Berkeley |
Dr. David H Raulet |
Transplantation Immunology |
Inactivating NK cell reactivity to facilitate transplantation of stem cell derived tissue |
$952,896 |
| Stanford University |
Dr. Robert Negrin MD |
Transplantation Immunology |
Regulatory T cell induced tolerance to ESC transplantation |
$1,382,658 |
| University of California, San Diego |
Prof. Martin Marsala |
Transplantation Immunology |
Induction of immune tolerance after spinal grafting of human ES-derived neural precursors |
$1,387,800 |
| Cedars-Sinai Medical Center |
Dr. Terrence Town |
Transplantation Immunology |
Role of HLA in neural stem cell rejection using humanized mice |
$1,119,385 |
| University of Southern California |
Dr. Terrence Christopher Town |
Transplantation Immunology |
Role of HLA in neural stem cell rejection using humanized mice |
$353,249 |
| Stanford University |
Professor Christopher H. Contag |
Transplantation Immunology |
Engineering Embryonic Stem Cell Allografts for Operational Tolerance |
$1,411,338 |
| University of California, San Diego |
Dr. Yang Xu |
Transplantation Immunology |
Induction of immune tolerance to human embryonic stem cell-derived allografts |
$1,192,680 |
| University of California, Los Angeles |
UCLA Gay M Crooks |
Transplantation Immunology |
Engineering Thymic Regeneration to Induce Tolerance |
$1,235,445 |
| University of California, Davis |
Dr. William J Murphy |
Transplantation Immunology |
Donor natural killer (NK) cells as “veto” cells to promote donor-specific tolerance |
$1,257,601 |
| Palo Alto Veterans Institute for Research |
Dr. Husein Hadeiba |
Transplantation Immunology |
Application of Tolerogenic Dendritic Cells for Hematopoietic Stem Cell Transplantation |
$733,061 |
| Escape Therapeutics, Inc |
Basil M Hantash |
Transplantation Immunology |
Development of an immune tolerant hESC source for allogeneic cell therapy applications |
$1,453,040 |
| La Jolla Institute for Allergy and Immunology |
Dr. Anjana Rao |
Transplantation Immunology |
Generation of regulatory T cells by reprogramming |
$1,464,446 |
| University of California, San Francisco |
Dr. Tippi C. MacKenzie |
Transplantation Immunology |
Maternal and Fetal Immune Responses to In Utero Hematopoietic Stem Cell Transplantation |
$1,230,869 |
| Scripps Research Institute |
Dr. Jeanne F Loring |
Transplantation Immunology |
Thymus based tolerance to stem cell therapies |
$1,108,921 |
| Stanford University |
Dr. Judith A Shizuru |
Transplantation Immunology |
Purified allogeneic hematopoietic stem cells as a platform for tolerance induction |
$1,233,275 |
| University of California, San Francisco |
Dr. Jeffrey A Bluestone |
Transplantation Immunology |
Stem cell tolerance through the use of engineered antigen-specific regulatory T cells |
$1,152,768 |
| University of California, San Francisco |
Dr. Mark S. Anderson |
Transplantation Immunology |
Stem cell differentiation to thymic epithelium for inducing tolerance to stem cells |
$1,314,089 |
| University of California, San Diego |
Dr. Ying Liu |
Tools and Technologies I |
Generation of disease models for neurodegenerative disorders in hESCs by gene targeting |
$709,829 |
| University of California, Davis |
Kit S Lam |
Tools and Technologies I |
Discovery of adhesion ligands for pluripotent human stem cells |
$834,003 |
| ViaCyte, Inc. |
Dr. Evert Kroon |
Tools and Technologies I |
Development of the Theracyte Cellular Encapsulation System for Delivery of human ES Cell-derived Pancreatic Islets and Progenitors. |
$827,072 |
| University of California, Irvine |
Dr. Lisa A Flanagan |
Tools and Technologies I |
Novel Separation of Stem Cell Subpopulations |
$861,122 |
| University of California, Berkeley |
Dr. Steven M. Conolly |
Tools and Technologies I |
Magnetic Particle Imaging: A Novel Ultra-sensitive Imaging Scanner
for Tracking Stem Cells In Vivo |
$858,345 |
| University of Southern California |
Dr. Pin Wang |
Tools and Technologies I |
Development of Baculoviral Vectors for Gene Editing of Human Stem Cells |
$945,604 |
| Gamma Medica-Ideas, Inc. |
Douglas Jay Wagenaar |
Tools and Technologies I |
A Novel SPECT Microscopy System for 3D Imaging of Single Stem Cells In Vivo |
$800,065 |
| University of California, Davis |
Dr. Alice F Tarantal |
Tools and Technologies I |
In Vivo Imaging for the Detection and Quantitation of Transplanted Stem/Progenitor Cells in Nonhuman Primates |
$799,350 |
| University of California, Merced |
Dr. Michael Cleary |
Tools and Technologies I |
RNA Analysis by Biosynthetic Tagging (RABT): a tool for the identification of cell type-specific RNAs |
$481,096 |
| Stanford University |
Professor Helen M. Blau PhD |
Tools and Technologies I |
Regulation of Stem Cell Fate in Bioengineered Arrays of Hydrogel Microwells |
$949,608 |
| City of Hope, Beckman Research Institute |
Joseph Shi Gold |
Tools and Technologies I |
Development of Suspension Adaptation, Scale-up cGMP Banking and Cell Characterization Technologies for hESC Lines |
$882,929 |
| Vala Sciences, Inc. |
Dr. Patrick McDonough |
Tools and Technologies I |
Optimization in the Identification, Selection and Induction of Maturation of Subtypes of Cardiomyocytes derived from Human Embryonic Stem Cells |
$870,717 |
| University of California, Los Angeles |
Dr. Michael E. Phelps |
Tools and Technologies I |
Novel Tools and Technologies for Translational PET Imaging of Cell-based Therapies |
$914,039 |
